Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK)
inhibitor that was approved by the FDA for the treatment of renal cell ...
SUTENT® (sunitinib malate) for treatment of advanced renal cell carcinoma,
gastrointestinal stromal tumors & advanced pancreatic NET. Risk info for
Aug 15, 2016 ... Sunitinib: learn about side effects, dosage, special precautions, and more on
Trade Name: Sutent <sup>®</sup> Other Name: SU11248. Drug Type: Sunitinib is a targeted
therapy and is a receptor protein-tyrosine kinase inhibitor. It inhibits the actions ...
May 12, 2015 ... Read about the cancer treatment drug sunitinib, otherwise known as Sutent,
including what it is, how it works and possible side effects.
Oct 5, 2006 ... This page contains brief information about sunitinib malate and a collection of
links to more information about the use of this drug, research ...
Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor
receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and ...
Sunitinib is an oral oxindole multitargeted kinase inhibitor that inhibits certain
receptor tyrosine kinases (RTKs). These include vascular endothelial growth
Jan 6, 2017 ... Easy to read patient leaflet for sunitinib. Includes indications, proper use, special
instructions, precautions, and possible side effects.
SUTENT, an oral multi-kinase inhibitor, is the malate salt of sunitinib. Sunitinib
malate is described chemically as Butanedioic acid, hydroxy-, (2S)-, compound ...